


Recent Drug Overdose Data Trends

Substance Use Epidemiology Section New Mexico Department of Health



Drug Overdose Death Past 12-Month Running Totals by Substance, New Mexico, 2021-June 2025



Source: New Mexico Department of Health Bureau of Vital Records & Health Statistics death certificate data Each point represents the sum of the prior 12 months.


 $2024\,\&\,2025\,data$ are provisional and subject to change.

 $Drug\ overdoses\ typically\ involve\ more\ than\ one\ substance,\ so\ counts\ by\ drug\ type\ are\ not\ mutually\ exclusive.$

Fentanyl-involved drug overdose deaths include fentanyl and its analogues.









Source: New Mexico Department of Health Bureau of Vital Records & Health Statistics death certificate data Each point represents the sum of the prior 12 months.

2024 & 2025 data are provisional and subject to change.







 $Source: New \, Mexico \, Department \, of \, Health \, Bureau \, of \, Vital \, Records \, \& \, Health \, Statistics \, death \, certificate \, data.$

Drug overdose deaths are identified through ICD-10 codes X40-X44, X60-X64, X85, & Y10-Y14.

Drug overdoses typically involve more than one substance, so counts by drug type are not mutually exclusive.

Fentanyl-involved drug overdose deaths include fentanyl and its analogues.

2024 & 2025 data are provisional and thus subject to change. 2025 Q2 data are only 55% coded as of 8/1/2025.

These data were analyzed & prepared by NMDOH Substance Use Epidemiology Section. For any questions, please email malinda.gowin@doh.nm.gov.



Drug Overdose Death Counts by Age Group, Doña Ana County, Rio Arriba County, Santa Fe County, & Taos County, New Mexico, 2024 Jan-June vs 2025 Jan-June



Source: New Mexico Department of Health Bureau of Vital Records & Health Statistics death certificate data. Drug overdose deaths are identified through ICD-10 codes X40-X44, X60-X64, X85, & Y10-Y14.


Data is only shown for age groups that had a notable increase in the first half of 2025 compared to the first half of 2024.

$2024\,\&\,2025\,data\,are\,provisional\,and\,thus\,subject\,to\,change.\,2025\,Q2\,data\,are\,only\,55\%\,coded\,as\,of\,8/1/2025.$

These data were analyzed & prepared by NMDOH Substance Use Epidemiology Section. For any questions, please email malinda.gowin@doh.nm.gov.








Source: New Mexico Department of Health Bureau of Vital Records & Health Statistics death certificate data. Drug overdose deaths are identified through ICD-10 codes X40-X44, X60-X64, X85, & Y10-Y14.

 $2024\,\&\,2025\,data\,are\,provisional\,and\,thus\,subject\,to\,change.\,2025\,Q2\,data\,are\,only\,55\%\,coded\,as\,of\,8/1/2025.$

 $These \ data \ were \ analyzed \ \& \ prepared \ by \ NMDOH \ Substance \ Use \ Epidemiology \ Section. \ For \ any \ questions, \ please \ email \ malinda. \ gowin@doh.nm.gov.$







Source: New Mexico Department of Health Bureau of Vital Records & Health Statistics death certificate data.

Drug overdose deaths are identified through ICD-10 codes X40-X44, X60-X64, X85, & Y10-Y14.

Race/ethnicity classifications were determined using the NMDOH 2013 race/ethnicity schema. NMDOH is currently in the process of updating the classifications due to changes in federal race/ethnicity standards.

Data is only shown for race/ethnicity groups that had a notable increase in the first half of 2025 compared to the first half of 2024.

2024 & 2025 data are provisional and thus subject to change. 2025 Q2 data are only 55% coded as of 8/1/2025.

These data were analyzed & prepared by NMDOH Substance Use Epidemiology Section. For any questions, please email malinda.gowin@doh.nm.gov.




Key Points -Mortality

- Overdose counts have risen consistently for Santa Fe & Taos counties since 2024Q1
- Fentanyl, methamphetamine & cocaine are driving the increases
- Increases are among older adults (55+) in Doña Ana, Rio Arriba, & Taos counties
- Those aged 35-44 in Santa Fe County & aged 25-34 in Taos County experienced the greatest increase
- Males in Taos County experienced the greatest increase
- Hispanic persons in Taos County & White persons in Santa Fe County experienced the greatest increases





- Originally intended for infectious disease surveillance
- In recent years, it has been adapted to monitor ED visits related to nonfatal drug overdose.
 - Has the advantage of providing more timely data
- Caveats to consider:
 - Stability of the number of reporting facilities (more complete in recent years)
 - Syndromic Surveillance in New Mexico has maintained a minimum of 80% of non-federal facilities reporting since 2019.
 - Does not include federal facilities (Veteran's Hospital and Indian Health Services)
 - Intended to provide a rough estimate of disease burden rather than an exact measure
 - Toxicology not consistently performed






 ${\bf Data\ source: NMDOH\ Syndromic\ Surveillance\ eReporting\ Files}$

These are not individual level data i.e. a person may visit the ED more than once in the specified period.

Total Drug Overdose visits include any overdose due to opioids, amphetamines, benzodiazepines, or cocaine based on finding those drug poisoning ICD-10-CM codes in any diagnosis field.






Data source: NMDOH Syndromic Surveillance eReporting Files

These are not individual level data i.e. a person may visit the ED more than once in the specified period.

Total Drug Overdose visits include any overdose due to opioids, amphetamines, benzodiazepines, or cocaine based on finding those drug poisoning ICD-10-CM codes in any diagnosis field.






 ${\bf Data\ source: NMDOH\ Syndromic\ Surveillance\ eReporting\ Files}$

These are not individual level data i.e. a person may visit the ED more than once in the specified period.

Opioid overdose related visits are defined based on finding ICD-10-CM codes for opioid poisoning in any diagnosis field (This category includes fentanyl, heroin, synthetic narcotics, etc).






Data source: NMDOH Syndromic Surveillance eReporting Files

These are not individual level data i.e. a person may visit the ED more than once in the specified period.

Opioid overdose related visits are defined based on finding ICD-10-CM codes for opioid poisoning in any diagnosis field (This category includes fentanyl, heroin, synthetic narcotics, etc).






 ${\bf Data\ source: NMDOH\ Syndromic\ Surveillance\ eReporting\ Files}$

These are not individual level data i.e. a person may visit the ED more than once in the specified period.

Total Drug Overdose visits include any overdose due to opioids, amphetamines, benzodiazepines, or cocaine based on finding those drug poisoning ICD-10-CM codes in any diagnosis field.


Only age groups with notable increases are shown.





These are not individual level data i.e. a person may visit the ED more than once in the specified period.

Total Drug Overdose visits include any overdose due to opioids, amphetamines, benzodiazepines, or cocaine based on finding those drug poisoning ICD-10-CM codes in any diagnosis field.





Data source: NMDOH Syndromic Surveillance eReporting Files

These are not individual level data i.e. a person may visit the ED more than once in the specified period.

Total Drug Overdose visits include any overdose due to opioids, amphetamines, benzodiazepines, or cocaine based on finding those drug poisoning ICD-10-CM codes in any diagnosis field.


Race/ethnicity classifications were determined using the NMDOH 2013 race/ethnicity schema. NMDOH is currently in the process of updating the classifications due to changes in federal race/ethnicity standards. Asian/Pl and AA/Black race/ethnicity groups were suppressed due to very small numbers (<2 visits per county).

Key Points – ED Visits

- ED Data (eReporting): notable increases in ODrelated ED visits were observed in 2025Q1 & Q2 for Rio Arriba, Santa Fe, and Taos Counties
 - · Driven by opioids
- Dona Ana County remained stable
- Pilot ESSENCE Data (not shown): all 4 counties have elevated OD-related ED visits in 2025Q1 and Q2
 - The increases are not as significant for Rio Arriba and Taos Counties
 - Only Dona Ana County has an additional increase from 2025Q1 to Q2




- There were 7 ODs in Santa Fe County on 2/01/2025 though they appear to be unrelated events based on clinical impression descriptions
- Based on brief abstraction* of the 4 counties' 2025 Q1 data:
 - 13% of the OD visits had an indication of homelessness (22% in Santa Fe County)
 - 25% of OD visits indicated polysubstance use (48% in Taos County)
 - Polysubstance combinations in Taos County were often opioids and stimulants (34%) or opioids and alcohol (24%)
 - 4 OD visits were for currently incarcerated persons
 - 12 OD visits were repeat visits (same individual within the same quarter)
 - For Rio Arriba and Santa Fe Counties where triage notes/clinical impression fields were more complete, >60% of the visits indicated naloxone use prior to ED intake






Data Source: NM HCA Medicaid Program, NM DOH Co-Prescription Pilot Programs, NM DOH Harm Reduction Program, NM HCA BHSD Office of Substance Abuse Prevention (OSAP). This data was analyzed & prepared by NMDOH Substance Use Epidemiology Section. Please contact Sahejpreet Gill at sahejpreet Gill at sahejpreet gill @doh.nm.gov for any questions regarding the data in this table.

^{**}The data are an underrepresentation of the number of units of naloxone distributed due to only having one insurance source and no direct data from all retail pharmacies. Naloxone became available for purchase over the counter in Sept 2023, but data on those purchases are not available.






 $Data Source: NM HCA \, Medicaid \, Program, \, NM \, DOH \, Co-Prescription \, Pilot \, Programs, \, NM \, DOH \, Harm \, Reduction \, Program, \, NM \, HCA \, BHSD \, Office \, of \, Substance \, Abuse \, Prevention \, (OSAP). \, This \, data \, was \, analyzed \, \& \, prepared \, by \, NMDOH \, Substance \, Use \, Epidemiology \, Section. \, Please \, contact \, Sahejpreet \, Gill \, at \, sahejpreet \, .gill \, @doh.nm.gov \, for \, any \, questions \, and \, Sahejpreet \, .gill \, at \, Sahejpreet \, .gill \, .gill \, at \, Sahejpreet \, .gill \, .gill$







*The data are an underrepresentation of the number of units of naloxone distributed due to only having one insurance source and no direct data from all retail pharmacies. Naloxone became available for purchase over the counter in Sept 2023, but data on those purchases are not available.

2024Q3

Quarter

2024Q4


2025Q1

2025Q2

2024Q1

2024Q2


 $Data Source: NM HCA \, Medicaid \, Program, \, NM \, DOH \, Co-Prescription \, Pilot \, Programs, \, NM \, DOH \, Harm \, Reduction \, Program, \, NM \, HCA \, BHSD \, Office \, of \, Substance \, Abuse \, Prevention \, (OSAP). \, This \, data \, was \, analyzed \, \& \, prepared \, by \, NMDOH \, Substance \, Use \, Epidemiology \, Section. \, Please \, contact \, Sahejpreet \, Gill \, at \, sahejpreet \, Gill \, Abuse \, Governor \, Gram \, G$





 $Data Source: NM HCA \, Medicaid \, Program, \, NM \, DOH \, Co-Prescription \, Pilot \, Programs, \, NM \, DOH \, Harm \, Reduction \, Program, \, NM \, HCA \, BHSD \, Office \, of \, Substance \, Abuse \, Prevention \, (OSAP). \, This \, data \, was \, analyzed \, \& \, prepared \, by \, NMDOH \, Substance \, Use \, Epidemiology \, Section. \, Please \, contact \, Sahejpreet \, Gill \, at \, Sahejpreet \, Gill \, Abuse \, Gill$

^{*}The data are an underrepresentation of the number of units of naloxone distributed due to only having one insurance source and no direct data from all retail pharmacies. Naloxone became available for purchase over the counter in Sept 2023, but data on those purchases are not available.





Quarter

2024Q3

2024Q4

2025Q1


2025Q2


2024Q1

2024Q2

Data Source: NM HCA Medicaid Program, NM DOH Co-Prescription Pilot Programs, NM DOH Harm Reduction Program, NM HCA BHSD Office of Substance Abuse Prevention (OSAP). This data was analyzed & prepared by NMDOH Substance Use Epidemiology Section. Please contact Sahejpreet Gill at sahejpreet.gill@doh.nm.gov for any questions regarding the data in this table.


^{*}The data are an underrepresentation of the number of units of naloxone distributed due to only having one insurance source and no direct data from all retail pharmacies. Naloxone became available for purchase over the counter in Sept 2023, but data on those purchases are not available.





 $Data Source: NM HCA \, Medicaid \, Program, \, NM \, DOH \, Co-Prescription \, Pilot \, Programs, \, NM \, DOH \, Harm \, Reduction \, Program, \, NM \, HCA \, BHSD \, Office \, of \, Substance \, Abuse \, Prevention \, (OSAP). \, This \, data \, was \, analyzed \, \& \, prepared \, by \, NMDOH \, Substance \, Use \, Epidemiology \, Section. \, Please \, contact \, Sahejpreet \, Gill \, at \, sahejpreet \,$






^{*}The data are an underrepresentation of the number of units of naloxone distributed due to only having one insurance source and no direct data from all retail pharmacies. Naloxone became available for purchase over the counter in Sept 2023, but data on those purchases are not available.

Data Source: NM HCA Medicaid Program, NM DOH Co-Prescription Pilot Programs, NM DOH Harm Reduction Program, NM HCA BHSD Office of Substance Abuse Prevention (OSAP). This data was analyzed & prepared by NMDOH Substance Use Epidemiology Section. Please contact Sahejpreet Gill at sahejpreet.gill@doh.nm.gov for any questions regarding the data in this table.



NMHealth


Naloxone Reversals* by Quarter, New Mexico 2024Q1 - 2025Q2



Data Source: NM HCA Medicaid Program, NM DOH Co-Prescription Pilot Programs, NM DOH Harm Reduction Program, NM HCA BHSD Office of Substance Abuse Prevention (OSAP), Law Enforcement.

*The data are an underrepresentation of the number of reported reversals as the majority of reversals reported comes from NMDOH Harm Reduction data. Emergency Medical Services, law enforcement, and other layperson reversal data are not often captured. Reversals are defined as a patient outcome of "Ok." Reversals are not individual level data i.e. the same person may have been reversed more than once in the time period.

This data was analyzed & prepared by NMDOH Substance Use Epidemiology Section. Please contact Sahejpreet Gill at sahejpreet.gill@doh.nm.gov for any questions regarding this data.





 $Data Source: NM HCA \ Medicaid \ Program, NM DOH \ Co-Prescription \ Pilot \ Programs, NM DOH \ Harm \ Reduction \ Programs, NM HCA \ BHSD \ Office of Substance \ Abuse \ Prevention (OSAP), Law \ Enforcement. This data was analyzed \ prepared by NMDOH \ Substance \ Use \ Epidemiology \ Section. Please \ contact \ Sahejpreet \ Gill \ at \ sahejpreet \ Gill \ at \ sahejpreet \ Gill \ doh.nm.gov \ for \ any \ questions \ regarding \ the \ data \ in \ this \ table.$

^{*}This data is an underrepresentation of the number of reported reversals because Emergency Medical Services, law enforcement, and other agencies are not always included, Reversals are defined as a patient outcome of "Ok." Reversals are not individual level data i.e. the same person may have been reversed more than once in the time period.





Naloxone Distribution

- Has been decreasing from DOH in Taos County since Q3 of 2024
- Has been decreasing from BHSD in Dona Ana County since Q3 of 2024
- Has been slightly decreasing from Medicaid in Rio Arriba from Q2 2024 to Q1 2025 but has been slightly increasing in Q2 of 2025

Naloxone Reversals

- Have remained steady in Dona Ana and Taos county from 2024 to Q2 of 2025
- Were steady in 2024 but have increased from Q1 to Q2 of 2025 in Rio Arriba
- Increased from Q2 2024 until Q1 2025 and now seem to be decreasing in Santa Fe




Treatment Data

- The New Mexico Board of Pharmacy (BoP) Prescription Monitoring Program (PMP)
 - These are controlled substance and gabapentin prescriptions only.
 - Buprenorphine prescriptions are counted as treatment prescriptions if they have a length of at least 10 days.
 - If a prescription is filled, it does not imply that the patient took the prescription.

Count of Buprenorphine Prescriptions Filled by Quarter, New Mexico, 2024Q1-2025Q2






Data source: NM Board of Pharmacy (BoP) Prescription Monitoring Program (PMP), analyzed by the NM BoP PMP.

 $This \, data \, is \, counts \, of \, \, prescription \, filled. \, A \, prescription \, being \, filled \, and \, picketed \, up \, by \, a \, patient \, does \, not \, imply \, that \, individual \, took \, the \, prescription.$

Prescriptions were only counted if they had a prescription length was 10 days or longer.

Count of Buprenorphine Prescriptions Filled by Quarter, Doña Ana County, Rio Arriba County, Santa Fe County, and Taos County, 2024Q1-2025Q2






Data source: NM Board of Pharmacy (BoP) Prescription Monitoring Program (PMP), analyzed by the NM BoP PMP.

This data is counts of prescription filled. A prescription being filled and picketed up by a patient does not imply that individual took the prescription.

Prescriptions were only counted if they had a prescription length was 10 days or longer.


Count of Unique Patients that had Buprenorphine Prescriptions Filled by Quarter, New Mexico, NMHealth



Data source: NM Board of Pharmacy (BoP) Prescription Monitoring Program (PMP), analyzed by the NM BoP PMP.

This data is counts of unique patients that had a prescription filled. A prescription being filled and picketed up by a patient does not imply that individual took the prescription. Unique patients were only counted if prescription length was 10 days or longer.

Count of Unique Patients that had Buprenorphine Prescriptions Filled by Quarter, Doña Ana County, Rio Arriba County, Santa Fe County, and Taos County, 2024Q1-2025Q2



Data source: NM Board of Pharmacy (BoP) Prescription Monitoring Program (PMP), analyzed by the NM BoP PMP.

This data is counts of unique patients that had a prescription filled. A prescription being filled and picketed up by a patient does not imply that individual took the prescription. Unique patients were only counted if prescription length was 10 days or longer.



Patient Counts

- New Mexico count is stable.
 - 2% 2024q1-2025q1.
 - 5% 2024q2-2025q2.
- Taos County has decreased.
 - -15% 2024q1-2025q1.
 - -10% 2024q2-2025q2.
- Other counties are stable.



Prescription Counts

- New Mexico count has increased.
 - 8% 2024q1-2025q1.
 - 7% 2024q2-2025q2.
- Doña Ana County has increased.
 - 5% 2024q1-2025q1.
 - 12% 2024q2-2025q2.
- Other counties are stable.





Substance Use Epidemiology Section Manager:

Luigi.GarciaSaavedr@doh.nm.gov

Drug Surveillance Unit

Percis Drew

Sahejpreet Gill

Malinda Gowin

Hayley Peterson

Sangam Shrestha